{"id":1470,"date":"2020-07-01T06:35:55","date_gmt":"2020-07-01T06:35:55","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=1470"},"modified":"2023-08-29T18:02:02","modified_gmt":"2023-08-29T18:02:02","slug":"fda-development-pathway-alterity-therapeutics-drug-treat-multiple-system-atrophy","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=1470","title":{"rendered":"FDA\u4e3aAlterity Therapeutics\u516c\u53f8\u6cbb\u7597\u591a\u7cfb\u7edf\u840e\u7f29\u7684\u836f\u7269\u63d0\u4f9b\u4e86\u5f00\u53d1\u9014\u5f84"},"content":{"rendered":"<p>\u66ff\u4ee3\u836f\u7269\u5f00\u53d1\u5546<a href=\"http:\/\/smallcaps-production.test\/stocks\/?symbol=ATH&amp;lang=cn\">Alterity Therapeutics (ASX: ATH<\/a>)\u5df2\u7ecf\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40(FDA)\u5173\u4e8e\u5176\u591a\u7cfb\u7edf\u840e\u7f29(MSA)\u5b9e\u9a8c\u6cbb\u7597\u7684\u53d1\u5c55\u8def\u5f84\u7684\u6307\u5bfc\uff0cMSA\u662f\u4e00\u79cd\u76ee\u524d\u5c1a\u672a\u83b7\u5f97\u6279\u51c6\u6cbb\u7597\u7684\u5e15\u91d1\u68ee\u75c5\u3002<\/p>\n<p>\u8be5\u516c\u53f8\u5728ASX\u548c\u7eb3\u65af\u8fbe\u514b\u4e24\u5730\u4e0a\u5e02(\u80a1\u7968\u4ee3\u7801\u4e3aATHE)\uff0c\u53bb\u5e74\u6210\u529f\u5b8c\u6210\u4e3b\u8981\u5019\u9009\u836f\u7269ATH434\u7684\u4e00\u671f\u4e34\u5e8a\u8bd5\u9a8c\u540e\uff0c\u8be5\u516c\u53f8\u4e0eFDA\u8fdb\u884c\u4e86\u4f1a\u9762\u3002<\/p>\n<p>\u4f1a\u8bae\u7684\u76ee\u7684\u662f\u83b7\u53d6\u8be5\u5316\u5408\u7269\u4e34\u5e8a\u5f00\u53d1\u8ba1\u5212\u7684\u4fe1\u606f\uff0c\u5e76\u4e3aAlterity\u63a5\u6536\u5176\u4e8c\u671f\u7814\u7a76\u8bbe\u8ba1\u7684\u53cd\u9988\u3002<\/p>\n<p>\u4f1a\u8bae\u5f97\u51fa\u7684\u7ed3\u8bba\u5305\u62ec\u652f\u6301\u7b2c\u4e8c\u9636\u6bb5\u7814\u7a76\u6240\u9700\u7684\u975e\u4e34\u5e8a\u7814\u7a76\u7684\u5171\u8bc6\uff0c\u4ee5\u53caFDA\u5bf9\u7814\u7a76\u8bbe\u8ba1\u5173\u952e\u65b9\u9762\u7684\u652f\u6301\uff0c\u5305\u62ec\u63d0\u8bae\u7684\u60a3\u8005\u7fa4\u4f53\u3001\u5b89\u5168\u6027\u76d1\u6d4b\u8ba1\u5212\u548c\u8bd5\u9a8c\u671f\u95f4\u836f\u7269\u66b4\u9732\u8bc4\u4f30\u7b56\u7565\u3002<\/p>\n<p>Alterity\u9996\u5e2d\u533b\u7597\u5b98David Stamler\u535a\u58eb\u8868\u793a\uff0c\u8fd9\u6b21\u4f1a\u8bae\u4e3a\u516c\u53f8\u5f00\u5c55\u4e8c\u671f\u7814\u7a76\u63d0\u4f9b\u4e86\u201c\u660e\u786e\u7684\u524d\u8fdb\u9053\u8def\u201d\u3002<\/p>\n<p>\u4ed6\u8bf4:\u201cFDA\u6e05\u695a\u5730\u8ba4\u8bc6\u5230MSA\u7684\u4e25\u91cd\u6027\uff0c\u4e5f\u8ba4\u8bc6\u5230\u9700\u8981\u65b0\u7684\u6cbb\u7597\u65b9\u6cd5\u6765\u89e3\u51b3\u8fd9\u79cd\u6bc1\u706d\u6027\u7684\u5b64\u513f\u75c5\u3002\u201d<\/p>\n<h2>\u6ca1\u6709\u6279\u51c6\u6cbb\u7597MSA<\/h2>\n<p>MSA\u662f\u4e00\u79cd\u7f55\u89c1\u7684\u3001\u8fdb\u5c55\u8fc5\u901f\u7684\u795e\u7ecf\u7cfb\u7edf\u75be\u75c5\uff0c\u5f71\u54cd\u6210\u5e74\u4eba\uff0c\u6ca1\u6709\u5df2\u77e5\u7684\u539f\u56e0\u3002<\/p>\n<p>\u8fd9\u79cd\u60c5\u51b5\u4e0e\u5e15\u91d1\u68ee\u6c0f\u75c7\u60a3\u8005\u8868\u73b0\u51fa\u7c7b\u4f3c\u7684\u8fd0\u52a8\u75c7\u72b6\uff0c\u5982\u808c\u8089\u5931\u53bb\u63a7\u5236\u3002<\/p>\n<p>\u60a3\u6709MSA\u7684\u4e2a\u4f53\u8fd8\u53ef\u80fd\u5931\u53bb\u534f\u8c03\u81ea\u4e3b\u8fd0\u52a8\u7684\u80fd\u529b\uff0c\u5e76\u4f53\u9a8c\u5230\u4e0d\u81ea\u4e3b\u8eab\u4f53\u529f\u80fd\u7684\u8c03\u8282\u529f\u80fd\u53d7\u635f\uff0c\u5305\u62ec\u8840\u538b\u3001\u80a0\u9053\u548c\u8180\u80f1\u63a7\u5236\u3002<\/p>\n<p>\u4e0d\u5e78\u7684\u662f\uff0c\u6cbb\u7597\u5e15\u91d1\u68ee\u6c0f\u75c7\u7684\u836f\u7269\u5e76\u4e0d\u80fd\u89e3\u51b3\u5927\u591a\u6570\u8fd9\u4e9b\u75c7\u72b6\u3002<\/p>\n<p>\u7531\u4e8e\u6ca1\u6709\u6279\u51c6\u7684\u6cbb\u7597MSA\uff0c\u4e5f\u6ca1\u6709\u5173\u4e8e\u53ef\u63a5\u53d7\u7684\u7597\u6548\u7ec8\u70b9\u7684\u76d1\u7ba1\u5148\u4f8b\u3002<\/p>\n<p>Alterity\u516c\u53f8\u8868\u793a\uff0c\u4ed6\u4eec\u5c06\u4e0eFDA\u5408\u4f5c\u5f00\u53d1\u6700\u9002\u5408MSA\u60a3\u8005\u7814\u7a76\u7684\u7ec8\u672b\u70b9\u3002<\/p>\n<h2>\u81ea\u7136\u5386\u53f2\u7814\u7a76<\/h2>\n<p>\u4e3a\u4e86\u5f00\u53d1MSA\u4e34\u5e8a\u7814\u7a76\u7684\u7ec8\u70b9\uff0cFDA\u9f13\u52b1Alterity\u4f7f\u7528\u5176\u4e0e\u7530\u7eb3\u897f\u5dde\u7eb3\u4ec0\u7ef4\u5c14\u8303\u5fb7\u6bd4\u5c14\u7279\u5927\u5b66\u533b\u5b66\u4e2d\u5fc3\u4e34\u5e8a\u548c\u795e\u7ecf\u6210\u50cf\u4e13\u5bb6\u8ba1\u5212\u7684\u81ea\u7136\u5386\u53f2\u7814\u7a76\u6570\u636e\u3002<\/p>\n<p>\u8fd9\u9879\u540d\u4e3abioMUSE\u7684\u7814\u7a76\u5c06\u62db\u52df\u65e9\u671fMSA\u60a3\u8005\uff0c\u5e76\u5bf9\u4e34\u5e8a\u53c2\u6570\u548c\u751f\u7269\u6807\u5fd7\u7269\u7684\u53d8\u5316\u8fdb\u884c\u957f\u8fbe\u4e00\u5e74\u7684\u8ddf\u8e2a\u3002<\/p>\n<p>\u6839\u636eAlterity\uff0c\u8be5\u7814\u7a76\u5bf9\u4e8e\u786e\u5b9a\u6240\u9009\u60a3\u8005\u7fa4\u4f53\u7684\u75be\u75c5\u8fdb\u5c55\u7279\u5f81\u548c\u4f18\u5316\u4e34\u5e8a\u8bd5\u9a8c\u8bbe\u8ba1\u5f88\u91cd\u8981\u3002<\/p>\n<h2>\u56fd\u9645\u76d1\u7ba1\u7b56\u7565<\/h2>\n<p>Alterity\u4e5f\u5728\u6b27\u6d32\u548c\u6fb3\u5927\u5229\u4e9a\u5bfb\u6c42\u76d1\u7ba1\u9014\u5f84\uff0c\u8ba1\u5212\u4e0e\u6b27\u6d32\u5f53\u5c40\u4f1a\u9762\u3002<\/p>\n<p>\u201c\u8003\u8651\u5230\u65b0\u51a0\u75c5\u6bd2\u65f6\u4ee3\u7814\u7a76\u548c\u62db\u8058\u7684\u4e0d\u786e\u5b9a\u6027\uff0c\u4ee5\u53ca\u9700\u8981\u5c06\u53d7\u5f71\u54cd\u6700\u5c0f\u7684\u5730\u70b9\u4f5c\u4e3a\u76ee\u6807\uff0c\u516c\u53f8\u8c28\u614e\u5730\u5728\u4e16\u754c\u5404\u5730\u786e\u5b9a\u548c\u62db\u8058\u5730\u70b9\uff0c\u5e76\u4fdd\u6301\u9009\u62e9\u6027\uff0c\u201d\u5b83\u8bf4\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u66ff\u4ee3\u836f\u7269\u5f00\u53d1\u5546Alterity Therapeutics (ASX: ATH)\u5df2\u7ecf\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40(FDA)\u5173\u4e8e\u5176\u591a\u7cfb\u7edf\u840e\u7f29(MSA)\u5b9e\u9a8c\u6cbb\u7597\u7684\u53d1\u5c55\u8def\u5f84\u7684\u6307\u5bfc\uff0cMSA\u662f\u4e00\u79cd\u76ee\u524d\u5c1a\u672a\u83b7\u5f97\u6279\u51c6\u6cbb\u7597\u7684\u5e15\u91d1\u68ee\u75c5\u3002 \u8be5\u516c\u53f8\u5728ASX\u548c\u7eb3\u65af\u8fbe\u514b\u4e24\u5730\u4e0a\u5e02(\u80a1\u7968\u4ee3\u7801\u4e3aATHE)\uff0c\u53bb\u5e74\u6210\u529f\u5b8c\u6210\u4e3b\u8981\u5019\u9009\u836f\u7269ATH434\u7684\u4e00\u671f\u4e34\u5e8a\u8bd5\u9a8c\u540e\uff0c\u8be5\u516c\u53f8\u4e0eFDA\u8fdb\u884c\u4e86\u4f1a\u9762\u3002 \u4f1a\u8bae\u7684\u76ee\u7684\u662f\u83b7\u53d6\u8be5\u5316\u5408\u7269\u4e34\u5e8a\u5f00\u53d1\u8ba1\u5212\u7684\u4fe1\u606f\uff0c\u5e76\u4e3aAlterity\u63a5\u6536\u5176\u4e8c\u671f\u7814\u7a76\u8bbe\u8ba1\u7684\u53cd\u9988\u3002 \u4f1a\u8bae\u5f97\u51fa\u7684\u7ed3\u8bba\u5305\u62ec\u652f\u6301\u7b2c\u4e8c\u9636\u6bb5\u7814\u7a76\u6240\u9700\u7684\u975e\u4e34\u5e8a\u7814\u7a76\u7684\u5171\u8bc6\uff0c\u4ee5\u53caFDA\u5bf9\u7814\u7a76\u8bbe\u8ba1\u5173\u952e\u65b9\u9762\u7684\u652f\u6301\uff0c\u5305\u62ec\u63d0\u8bae\u7684\u60a3\u8005\u7fa4\u4f53\u3001\u5b89\u5168\u6027\u76d1\u6d4b\u8ba1\u5212\u548c\u8bd5\u9a8c\u671f\u95f4\u836f\u7269\u66b4\u9732\u8bc4\u4f30\u7b56\u7565\u3002 Alterity\u9996\u5e2d\u533b\u7597\u5b98David Stamler\u535a\u58eb\u8868\u793a\uff0c\u8fd9\u6b21\u4f1a\u8bae\u4e3a\u516c\u53f8\u5f00\u5c55\u4e8c\u671f\u7814\u7a76\u63d0\u4f9b\u4e86\u201c\u660e\u786e\u7684\u524d\u8fdb\u9053\u8def\u201d\u3002 \u4ed6\u8bf4:\u201cFDA\u6e05\u695a\u5730\u8ba4\u8bc6\u5230MSA\u7684\u4e25\u91cd\u6027\uff0c\u4e5f\u8ba4\u8bc6\u5230\u9700\u8981\u65b0\u7684\u6cbb\u7597\u65b9\u6cd5\u6765\u89e3\u51b3\u8fd9\u79cd\u6bc1\u706d\u6027\u7684\u5b64\u513f\u75c5\u3002\u201d \u6ca1\u6709\u6279\u51c6\u6cbb\u7597MSA MSA\u662f\u4e00\u79cd\u7f55\u89c1\u7684\u3001\u8fdb\u5c55\u8fc5\u901f\u7684\u795e\u7ecf\u7cfb\u7edf\u75be\u75c5\uff0c\u5f71\u54cd\u6210\u5e74\u4eba\uff0c\u6ca1\u6709\u5df2\u77e5\u7684\u539f\u56e0\u3002 \u8fd9\u79cd\u60c5\u51b5\u4e0e\u5e15\u91d1\u68ee\u6c0f\u75c7\u60a3\u8005\u8868\u73b0\u51fa\u7c7b\u4f3c\u7684\u8fd0\u52a8\u75c7\u72b6\uff0c\u5982\u808c\u8089\u5931\u53bb\u63a7\u5236\u3002 \u60a3\u6709MSA\u7684\u4e2a\u4f53\u8fd8\u53ef\u80fd\u5931\u53bb\u534f\u8c03\u81ea\u4e3b\u8fd0\u52a8\u7684\u80fd\u529b\uff0c\u5e76\u4f53\u9a8c\u5230\u4e0d\u81ea\u4e3b\u8eab\u4f53\u529f\u80fd\u7684\u8c03\u8282\u529f\u80fd\u53d7\u635f\uff0c\u5305\u62ec\u8840\u538b\u3001\u80a0\u9053\u548c\u8180\u80f1\u63a7\u5236\u3002 \u4e0d\u5e78\u7684\u662f\uff0c\u6cbb\u7597\u5e15\u91d1\u68ee\u6c0f\u75c7\u7684\u836f\u7269\u5e76\u4e0d\u80fd\u89e3\u51b3\u5927\u591a\u6570\u8fd9\u4e9b\u75c7\u72b6\u3002 \u7531\u4e8e\u6ca1\u6709\u6279\u51c6\u7684\u6cbb\u7597MSA\uff0c\u4e5f\u6ca1\u6709\u5173\u4e8e\u53ef\u63a5\u53d7\u7684\u7597\u6548\u7ec8\u70b9\u7684\u76d1\u7ba1\u5148\u4f8b\u3002 Alterity\u516c\u53f8\u8868\u793a\uff0c\u4ed6\u4eec\u5c06\u4e0eFDA\u5408\u4f5c\u5f00\u53d1\u6700\u9002\u5408MSA\u60a3\u8005\u7814\u7a76\u7684\u7ec8\u672b\u70b9\u3002 \u81ea\u7136\u5386\u53f2\u7814\u7a76 \u4e3a\u4e86\u5f00\u53d1MSA\u4e34\u5e8a\u7814\u7a76\u7684\u7ec8\u70b9\uff0cFDA\u9f13\u52b1Alterity\u4f7f\u7528\u5176\u4e0e\u7530\u7eb3\u897f\u5dde\u7eb3\u4ec0\u7ef4\u5c14\u8303\u5fb7\u6bd4\u5c14\u7279\u5927\u5b66\u533b\u5b66\u4e2d\u5fc3\u4e34\u5e8a\u548c\u795e\u7ecf\u6210\u50cf\u4e13\u5bb6\u8ba1\u5212\u7684\u81ea\u7136\u5386\u53f2\u7814\u7a76\u6570\u636e\u3002 \u8fd9\u9879\u540d\u4e3abioMUSE\u7684\u7814\u7a76\u5c06\u62db\u52df\u65e9\u671fMSA\u60a3\u8005\uff0c\u5e76\u5bf9\u4e34\u5e8a\u53c2\u6570\u548c\u751f\u7269\u6807\u5fd7\u7269\u7684\u53d8\u5316\u8fdb\u884c\u957f\u8fbe\u4e00\u5e74\u7684\u8ddf\u8e2a\u3002 \u6839\u636eAlterity\uff0c\u8be5\u7814\u7a76\u5bf9\u4e8e\u786e\u5b9a\u6240\u9009\u60a3\u8005\u7fa4\u4f53\u7684\u75be\u75c5\u8fdb\u5c55\u7279\u5f81\u548c\u4f18\u5316\u4e34\u5e8a\u8bd5\u9a8c\u8bbe\u8ba1\u5f88\u91cd\u8981\u3002 \u56fd\u9645\u76d1\u7ba1\u7b56\u7565 Alterity\u4e5f\u5728\u6b27\u6d32\u548c\u6fb3\u5927\u5229\u4e9a\u5bfb\u6c42\u76d1\u7ba1\u9014\u5f84\uff0c\u8ba1\u5212\u4e0e\u6b27\u6d32\u5f53\u5c40\u4f1a\u9762\u3002 \u201c\u8003\u8651\u5230\u65b0\u51a0\u75c5\u6bd2\u65f6\u4ee3\u7814\u7a76\u548c\u62db\u8058\u7684\u4e0d\u786e\u5b9a\u6027\uff0c\u4ee5\u53ca\u9700\u8981\u5c06\u53d7\u5f71\u54cd\u6700\u5c0f\u7684\u5730\u70b9\u4f5c\u4e3a\u76ee\u6807\uff0c\u516c\u53f8\u8c28\u614e\u5730\u5728\u4e16\u754c\u5404\u5730\u786e\u5b9a\u548c\u62db\u8058\u5730\u70b9\uff0c\u5e76\u4fdd\u6301\u9009\u62e9\u6027\uff0c\u201d\u5b83\u8bf4\u3002<\/p>\n","protected":false},"author":5,"featured_media":8438,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[403],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.3 (Yoast SEO v21.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FDA\u4e3aAlterity Therapeutics\u516c\u53f8\u6cbb\u7597\u591a\u7cfb\u7edf\u840e\u7f29\u7684\u836f\u7269\u63d0\u4f9b\u4e86\u5f00\u53d1\u9014\u5f84<\/title>\n<meta name=\"description\" content=\"\u66ff\u4ee3\u836f\u7269\u5f00\u53d1\u5546Alterity Therapeutics (ASX: ATH)\u5df2\u7ecf\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40(FDA)\u5173\u4e8e\u5176\u591a\u7cfb\u7edf\u840e\u7f29(MSA)\u5b9e\u9a8c\u6cbb\u7597\u7684\u53d1\u5c55\u8def\u5f84\u7684\u6307\u5bfc\uff0cMSA\u662f\u4e00\u79cd\u76ee\u524d\u5c1a\u672a\u83b7\u5f97\u6279\u51c6\u6cbb\u7597\u7684\u5e15\u91d1\u68ee\u75c5\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA\u4e3aAlterity Therapeutics\u516c\u53f8\u6cbb\u7597\u591a\u7cfb\u7edf\u840e\u7f29\u7684\u836f\u7269\u63d0\u4f9b\u4e86\u5f00\u53d1\u9014\u5f84\" \/>\n<meta property=\"og:description\" content=\"\u66ff\u4ee3\u836f\u7269\u5f00\u53d1\u5546Alterity Therapeutics (ASX: ATH)\u5df2\u7ecf\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40(FDA)\u5173\u4e8e\u5176\u591a\u7cfb\u7edf\u840e\u7f29(MSA)\u5b9e\u9a8c\u6cbb\u7597\u7684\u53d1\u5c55\u8def\u5f84\u7684\u6307\u5bfc\uff0cMSA\u662f\u4e00\u79cd\u76ee\u524d\u5c1a\u672a\u83b7\u5f97\u6279\u51c6\u6cbb\u7597\u7684\u5e15\u91d1\u68ee\u75c5\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/fda-development-pathway-alterity-therapeutics-drug-treat-multiple-system-atrophy\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-01T06:35:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T18:02:02+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/07\/Alterity-Therapeutics-ASX-ATH-Parkinsons-orphan-drug-FDA.jpg\" \/>\n<meta name=\"author\" content=\"Small Caps\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"FDA\u4e3aAlterity Therapeutics\u516c\u53f8\u6cbb\u7597\u591a\u7cfb\u7edf\u840e\u7f29\u7684\u836f\u7269\u63d0\u4f9b\u4e86\u5f00\u53d1\u9014\u5f84\" \/>\n<meta name=\"twitter:description\" content=\"\u66ff\u4ee3\u836f\u7269\u5f00\u53d1\u5546Alterity Therapeutics (ASX: ATH)\u5df2\u7ecf\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40(FDA)\u5173\u4e8e\u5176\u591a\u7cfb\u7edf\u840e\u7f29(MSA)\u5b9e\u9a8c\u6cbb\u7597\u7684\u53d1\u5c55\u8def\u5f84\u7684\u6307\u5bfc\uff0cMSA\u662f\u4e00\u79cd\u76ee\u524d\u5c1a\u672a\u83b7\u5f97\u6279\u51c6\u6cbb\u7597\u7684\u5e15\u91d1\u68ee\u75c5\u3002\" \/>\n<meta name=\"twitter:image\" content=\"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/07\/Alterity-Therapeutics-ASX-ATH-Parkinsons-orphan-drug-FDA.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Small Caps\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/fda-development-pathway-alterity-therapeutics-drug-treat-multiple-system-atrophy\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/fda-development-pathway-alterity-therapeutics-drug-treat-multiple-system-atrophy\/\",\"name\":\"FDA\u4e3aAlterity Therapeutics\u516c\u53f8\u6cbb\u7597\u591a\u7cfb\u7edf\u840e\u7f29\u7684\u836f\u7269\u63d0\u4f9b\u4e86\u5f00\u53d1\u9014\u5f84\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2020-07-01T06:35:55+00:00\",\"dateModified\":\"2023-08-29T18:02:02+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74\"},\"description\":\"\u66ff\u4ee3\u836f\u7269\u5f00\u53d1\u5546Alterity Therapeutics (ASX: ATH)\u5df2\u7ecf\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40(FDA)\u5173\u4e8e\u5176\u591a\u7cfb\u7edf\u840e\u7f29(MSA)\u5b9e\u9a8c\u6cbb\u7597\u7684\u53d1\u5c55\u8def\u5f84\u7684\u6307\u5bfc\uff0cMSA\u662f\u4e00\u79cd\u76ee\u524d\u5c1a\u672a\u83b7\u5f97\u6279\u51c6\u6cbb\u7597\u7684\u5e15\u91d1\u68ee\u75c5\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/fda-development-pathway-alterity-therapeutics-drug-treat-multiple-system-atrophy\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/fda-development-pathway-alterity-therapeutics-drug-treat-multiple-system-atrophy\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/fda-development-pathway-alterity-therapeutics-drug-treat-multiple-system-atrophy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA\u4e3aAlterity Therapeutics\u516c\u53f8\u6cbb\u7597\u591a\u7cfb\u7edf\u840e\u7f29\u7684\u836f\u7269\u63d0\u4f9b\u4e86\u5f00\u53d1\u9014\u5f84\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74\",\"name\":\"Small Caps\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g\",\"caption\":\"Small Caps\"},\"description\":\"Small Caps provides coverage on Australian ASX listed small cap stocks across all sectors: mining, resources, energy, biotech, technology, juniors and IPOs.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=5\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA\u4e3aAlterity Therapeutics\u516c\u53f8\u6cbb\u7597\u591a\u7cfb\u7edf\u840e\u7f29\u7684\u836f\u7269\u63d0\u4f9b\u4e86\u5f00\u53d1\u9014\u5f84","description":"\u66ff\u4ee3\u836f\u7269\u5f00\u53d1\u5546Alterity Therapeutics (ASX: ATH)\u5df2\u7ecf\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40(FDA)\u5173\u4e8e\u5176\u591a\u7cfb\u7edf\u840e\u7f29(MSA)\u5b9e\u9a8c\u6cbb\u7597\u7684\u53d1\u5c55\u8def\u5f84\u7684\u6307\u5bfc\uff0cMSA\u662f\u4e00\u79cd\u76ee\u524d\u5c1a\u672a\u83b7\u5f97\u6279\u51c6\u6cbb\u7597\u7684\u5e15\u91d1\u68ee\u75c5\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"FDA\u4e3aAlterity Therapeutics\u516c\u53f8\u6cbb\u7597\u591a\u7cfb\u7edf\u840e\u7f29\u7684\u836f\u7269\u63d0\u4f9b\u4e86\u5f00\u53d1\u9014\u5f84","og_description":"\u66ff\u4ee3\u836f\u7269\u5f00\u53d1\u5546Alterity Therapeutics (ASX: ATH)\u5df2\u7ecf\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40(FDA)\u5173\u4e8e\u5176\u591a\u7cfb\u7edf\u840e\u7f29(MSA)\u5b9e\u9a8c\u6cbb\u7597\u7684\u53d1\u5c55\u8def\u5f84\u7684\u6307\u5bfc\uff0cMSA\u662f\u4e00\u79cd\u76ee\u524d\u5c1a\u672a\u83b7\u5f97\u6279\u51c6\u6cbb\u7597\u7684\u5e15\u91d1\u68ee\u75c5\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/fda-development-pathway-alterity-therapeutics-drug-treat-multiple-system-atrophy\/","og_site_name":"smallcapsCN","article_published_time":"2020-07-01T06:35:55+00:00","article_modified_time":"2023-08-29T18:02:02+00:00","og_image":[{"url":"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/07\/Alterity-Therapeutics-ASX-ATH-Parkinsons-orphan-drug-FDA.jpg"}],"author":"Small Caps","twitter_card":"summary_large_image","twitter_title":"FDA\u4e3aAlterity Therapeutics\u516c\u53f8\u6cbb\u7597\u591a\u7cfb\u7edf\u840e\u7f29\u7684\u836f\u7269\u63d0\u4f9b\u4e86\u5f00\u53d1\u9014\u5f84","twitter_description":"\u66ff\u4ee3\u836f\u7269\u5f00\u53d1\u5546Alterity Therapeutics (ASX: ATH)\u5df2\u7ecf\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40(FDA)\u5173\u4e8e\u5176\u591a\u7cfb\u7edf\u840e\u7f29(MSA)\u5b9e\u9a8c\u6cbb\u7597\u7684\u53d1\u5c55\u8def\u5f84\u7684\u6307\u5bfc\uff0cMSA\u662f\u4e00\u79cd\u76ee\u524d\u5c1a\u672a\u83b7\u5f97\u6279\u51c6\u6cbb\u7597\u7684\u5e15\u91d1\u68ee\u75c5\u3002","twitter_image":"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/07\/Alterity-Therapeutics-ASX-ATH-Parkinsons-orphan-drug-FDA.jpg","twitter_misc":{"Written by":"Small Caps"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/fda-development-pathway-alterity-therapeutics-drug-treat-multiple-system-atrophy\/","url":"https:\/\/smallcapscn.x5view.co\/fda-development-pathway-alterity-therapeutics-drug-treat-multiple-system-atrophy\/","name":"FDA\u4e3aAlterity Therapeutics\u516c\u53f8\u6cbb\u7597\u591a\u7cfb\u7edf\u840e\u7f29\u7684\u836f\u7269\u63d0\u4f9b\u4e86\u5f00\u53d1\u9014\u5f84","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2020-07-01T06:35:55+00:00","dateModified":"2023-08-29T18:02:02+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74"},"description":"\u66ff\u4ee3\u836f\u7269\u5f00\u53d1\u5546Alterity Therapeutics (ASX: ATH)\u5df2\u7ecf\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40(FDA)\u5173\u4e8e\u5176\u591a\u7cfb\u7edf\u840e\u7f29(MSA)\u5b9e\u9a8c\u6cbb\u7597\u7684\u53d1\u5c55\u8def\u5f84\u7684\u6307\u5bfc\uff0cMSA\u662f\u4e00\u79cd\u76ee\u524d\u5c1a\u672a\u83b7\u5f97\u6279\u51c6\u6cbb\u7597\u7684\u5e15\u91d1\u68ee\u75c5\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/fda-development-pathway-alterity-therapeutics-drug-treat-multiple-system-atrophy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/fda-development-pathway-alterity-therapeutics-drug-treat-multiple-system-atrophy\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/fda-development-pathway-alterity-therapeutics-drug-treat-multiple-system-atrophy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"FDA\u4e3aAlterity Therapeutics\u516c\u53f8\u6cbb\u7597\u591a\u7cfb\u7edf\u840e\u7f29\u7684\u836f\u7269\u63d0\u4f9b\u4e86\u5f00\u53d1\u9014\u5f84"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74","name":"Small Caps","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g","caption":"Small Caps"},"description":"Small Caps provides coverage on Australian ASX listed small cap stocks across all sectors: mining, resources, energy, biotech, technology, juniors and IPOs.","url":"https:\/\/smallcapscn.x5view.co\/?author=5"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/1470"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1470"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/1470\/revisions"}],"predecessor-version":[{"id":8437,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/1470\/revisions\/8437"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/8438"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1470"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1470"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1470"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}